Introducing Esperity, the First Worldwide Social Media Network for
Cancer Patients

2013 BIO International Convention

2013 BIO International Convention:ESPERITY

April 17, 2013 11:13 AM Eastern Daylight Time

BRUSSELS--(BUSINESS WIRE)--At this year’s Bio International Convention, e-health company Esperity
will be introducing its ground-breaking social media network designed to
help cancer patients manage their health better, while connecting and
sharing information with other patients worldwide.

Due for launch later this year, Esperity’s online solution is currently
being validated by trial users and experts, including Stanford
University, John Hopkins University and the Bordet Institute in
Brussels. It is also gaining widespread interest from patient groups,
healthcare professionals and pharmaceutical companies. Founded by the
same team behind award-winning CPD patient site MiMedication, Esperity
was runner-up at the Eurotech Pitch Competition, November 2012.

Says CEO and co-founder Mitchell Silva: “Esperity fills a market need.
It gives cancer patients a simple way to monitor symptoms and manage
medication, while connecting with other patients worldwide, so they can
share information and feel less alone. It will also create a unique
knowledge base that will be useful to both patients and healthcare
professionals. Esperity is unique: as well as being the only dedicated
global social media networks for cancer patients, it supports over 30
languages.”

“Esperity also provides healthcare and pharmaceutical organisations a
way to add value to how they support patients, for instance as an
addition to patient adherence programmes. Esperity is a great complement
to the work that the healthcare community is already doing.”

Key features include: monitoring patterns, the disease’s progression,
drug interactions, or side effects to help patients manage their
healthcare better, plus reminder alerts to take the right medication at
the right time. Information can remain private, but patients can choose
to share selected data with the Esperity network, to help create a
global knowledge base. Esperity also enables patients to ‘twin’ with
people suffering from the same cancer, anywhere in the world, in much
the same way that people connect on Facebook.

Says Mitchell Silva, “Cancer patients often have limited time with
medical specialists and can feel isolated. Esperity provides patients
with a way to help themselves and potentially improve quality of life.”

Experienced entrepreneur Mitchell was inspired to become an e-health
innovator based on his own experience as a CPD patient. He holds a PhD
degree in bioscience engineering, while co-founder Erard le Beau de
Hemricourt is a MD specializing in nuclear medicine and has worked
closely with cancer patients. Esperity is based in Brussels, Belgium. www.esperity.com